{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:18:44Z","timestamp":1779322724608,"version":"3.51.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00484","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T12:05:16Z","timestamp":1586433916000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia"],"prefix":"10.3389","volume":"10","author":[{"given":"Andra","family":"Marcu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Colita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letitia Elena","family":"Radu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina Georgiana","family":"Jercan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Bica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minodora","family":"Asan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina Daniela","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen C.","family":"Diaconu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mambet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Botezatu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergiu","family":"Pasca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patric","family":"Teodorescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Anton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petruta","family":"Gurban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Colita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1182\/asheducation-2018.1.307","article-title":"JMML genomics and decisions","volume":"2018","author":"Niemayer","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/s41467\u2013017-02177-w","article-title":"RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia","volume":"8","author":"Lipka","year":"2017","journal-title":"Nat. Commun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2018\u201311-844688","article-title":"Juvenile myelomonocytic leukemia: who's the drive at the wheel?","volume":"133","author":"Niemeyer","year":"2019","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3324\/haematol.2015.138545","article-title":"Long-term serial xenotransplantation of juvenile myelomonocytic leukemia recapitulates human disease in Rag2-\/-\u03b3c-\/- mice","volume":"101","author":"Krombholz","year":"2016","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s11912\u2013003-0013-y","article-title":"Juvenile myelomonocytic leukemia","volume":"5","author":"Niemeyer","year":"2003","journal-title":"Curr Oncol Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/asheducation-2010.1.357","article-title":"Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia","volume":"2010","author":"Loh","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/j.1365\u20132141.2007.06958.x","article-title":"Paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia: molecular classification and treatment options","volume":"140","author":"Niemeyer","year":"2008","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1182\/blood-2014\u201308-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/17474086.2018.1421937","article-title":"Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia","volume":"11","author":"Locatelli","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3324\/haematol.2009.010355","article-title":"Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1","volume":"95","author":"Steinemann","year":"2010","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood-2009\u201301-198416","article-title":"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","volume":"114","author":"Loh","year":"2009","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1093\/hmg\/ddu148","article-title":"Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis","volume":"23","author":"Flex","year":"2014","journal-title":"Hum Mol Genet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1182\/blood-2010\u201308-298968","article-title":"European Working Group of Myelodysplastic Syndromes in Childhood (EWOG-MDS). aberrant DNA methylation characterizes juvenile myelomonocytic leukemia poor outcome","volume":"117","author":"Olk-Batz","year":"2011","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.4161\/epi.29941","article-title":"RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia","volume":"9","author":"Poetsch","year":"2014","journal-title":"Epigenetics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0145394","DOI":"10.1371\/journal.pone.0145394","article-title":"Aberrant DNA methylation is associated with a poor outcome in juvenile myelomonocytic leukemia","volume":"10","author":"Sakaguchi","year":"2015","journal-title":"PLoS ONE."},{"key":"B17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/15592294.2016.1145327","article-title":"Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia","volume":"11","author":"Wilhelm","year":"2016","journal-title":"Epigenetics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13148\u2013016-0216\u20133","article-title":"CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia","volume":"8","author":"Fluhr","year":"2016","journal-title":"Clin Epigenetics."},{"key":"B19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13148\u2013016-0237-y","article-title":"A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers","volume":"8","author":"Diesch","year":"2016","journal-title":"Clin Epigenetics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4161\/epi.1.1.2375","article-title":"Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications","volume":"1","author":"Mund","year":"2006","journal-title":"Epigenetics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrg2005","article-title":"Cancer epigenomics: DNA methylomes and histone-modification maps","volume":"8","author":"Steller","year":"2007","journal-title":"Nat Rev Genet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1023\/A:1011946030404","article-title":"DNA methylation as a target for drug design","volume":"15","author":"Bender","year":"1998","journal-title":"Pharm Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.18632\/oncotarget.1782","article-title":"Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.18632\/oncotarget.1542","article-title":"Alterations of immune response of nonsmall cell lung cancer with azacytidine","volume":"4","author":"Wrangle","year":"2013","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1182\/blood.V118.21.787.787","article-title":"5-azacytidine specifically depletes regulatory t cells (Tregs) in myelodysplastic syndrome (MDS) patients","volume":"118","author":"Costantini","year":"2011","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3324\/haematol.2014.109892","article-title":"Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia","volume":"100","author":"Niemeyer","year":"2015","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1182\/blood-2015\u201301-619734","article-title":"Bridging to transplant with azacytidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group","volume":"125","author":"Cseh","year":"2015","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fped.2014.00025","article-title":"Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation","volume":"2","author":"Dvorak","year":"2014","journal-title":"Front Pediatrics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/blood-2008\u201312-195693","article-title":"Intriguing response to azacytidine in a patient with juvenile myelomonocytic leukemia and monosomy 7","volume":"113","author":"Furlan","year":"2009","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"10031","DOI":"10.1200\/JCO.2019.37.15_suppl.10031","article-title":"Upfront azacitidine (AZA) in juvenile myelomonocytic leukemia (JMML): interim analysis of the prospective AZA-JMML-001 study","volume":"37","author":"Niemeyer","year":"2019","journal-title":"J Clin Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T12:05:18Z","timestamp":1586433918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":30,"alternative-id":["10.3389\/fonc.2020.00484"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00484","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]},"article-number":"484"}}